Interim CEO Stephen LaMond resigns; Executive Chairman Hoyoung Huh assumes CEO duties

Peak Bio, Inc.

Stephen LaMond resigned as Interim CEO and COO, effective Aug 31, 2024; will serve as consultant.
Separation agreement: $524,300 consulting fee paid in 24 monthly installments starting Sept 1, 2024.
LaMond receives option for 875,000 shares at $0.80 vesting in three tranches through Dec 31, 2025.
Board appoints Executive Chairman Hoyoung Huh to assume CEO responsibilities effective Aug 31, 2024.
Consulting fee includes $24,300 for 6 months of health coverage; COBRA for 18 months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Stephen LaMond

Interim Chief Executive Officer and Chief Operating Officer

Peak Bio, Inc.

Effective: 2024-08-31
Successor: Hoyoung Huh
Filed: September 3, 2024, 7:59 PM ET

Stephen LaMond, PharmD., MBA resigned from his positions as Interim Chief Executive Officer and Chief Operating Officer of Peak Bio, Inc. (the “Company”), effective August 31, 2024.

Appointed

Hoyoung Huh

Chief Executive Officer

Peak Bio, Inc.

Effective: 2024-08-31
Filed: September 3, 2024, 7:59 PM ET

the Company’s Board of Directors (the “Board”) determined that Hoyoung Huh, M.D., PhD, Executive Chairman of the Board, in his capacity as such, would assume the responsibilities of the Company’s chief executive officer, effective August 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen LaMond resigned as Interim Chief Executive Officer and Chief Operating Officer at Peak Bio, Inc..

Action: resigned
Role: Interim Chief Executive Officer and Chief Operating Officer

Exact text from the filing

Stephen LaMond, PharmD., MBA resigned from his positions as Interim Chief Executive Officer and Chief Operating Officer of Peak Bio, Inc. (the “Company”), effective August 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hoyoung Huh was appointed as Chief Executive Officer at Peak Bio, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Company’s Board of Directors (the “Board”) determined that Hoyoung Huh, M.D., PhD, Executive Chairman of the Board, in his capacity as such, would assume the responsibilities of the Company’s chief executive officer, effective August 31, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-102801

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.